NB-UVB Combination Therapy for Vitiligo

Compared to monotherapy with NB-UVB, combination treatments are more effective at promoting successful repigmentation and preventing treatment failure in vitiligo patients.

Vitiligo is characterized as an autoimmune disorder. Some management guidelines regarding vitiligo suggest the utilization of narrowband ultraviolet B (NB-UVB) combination therapies to promote skin repigmentation. This systematic review and meta-analysis, published in the Journal of Cosmetic Dermatology, aimed to evaluate the effectiveness of NB-UVB combination therapies for improving skin repigmentation in vitiligo patients.

The meta-analysis included a total of 28 studies with 1194 participants. The network meta-analysis compared NB-UVB with needling/microneedling, topical tacrolimus, oral Chinese herbal medicine, betamethasone intramuscular injection, carboxytherapy, and YAG laser with topical 5% 5-fluorouracil (5-FU) integrated with NB-UVB.

The network meta-analysis results revealed that combination therapies were more effective compared to monotherapy with NB-UVB, with excellent to complete response rates, accounting for ≥ 75%, for repigmentation of skin in vitiligo patients. The meta-analysis also highlighted that two combination therapies: NB-UVB plus topical 5% 5-FU and YAG laser, and NB-UVB plus microneedling/needling, were less likely to be associated with an ineffective treatment response of ≤25%.

In summary, the systematic review and meta-analysis demonstrated that all the combination therapies are more effective, as compared to monotherapy with NB-UVB, at promoting successful repigmentation and preventing treatment failure in vitiligo patients. The preferred combination therapies include NB-UVB with microneedling/needling and NB-UVB with YAG laser and topical 5% 5-FU.

Further clinical trials and case series may compare the effectiveness of NB-UVB combination therapies with surgical approaches in the context of vitiligo management, adverse effects, and treatment outcomes.

Reference

Zhu, B., Liu, C., Zhang, L., Wang, J., Chen, M., & Wei, Y. (2022). Comparison of NB-UVB combination therapy regimens for vitiligo: A systematic review and network meta-analysis. J Cosmet Dermatol. https://doi.org/10.1111/jocd.15534

Most Recent

Cardiovascular Disease

Cardiovascular Risk Management

Noninvasive Imaging Aids Selection of Stenosis Patients Needing Revascularization Procedure

CT fractional flow reserve analysis safely cuts rates of invasive procedures without compromising safety Computed tomography fractional flow reserve (CT-FFR) improves assessment of vessel blockages and reduces the number of stenosis patients referred for invasive revascularization procedures, according to a study published online April 4 in Radiology: Cardiothoracic Imaging. Mangun K. Randhawa, M.D., from Massachusetts General...

Oncology

Thyroid Cancer

GLP1 Receptor Agonist Use Does Not Seem to Increase Risk for Thyroid Cancer

No increased risk for thyroid cancer seen with use of GLP1 receptor agonist versus DPP4 inhibitor use, SGLT2 inhibitor use Glucagon-like peptide 1 (GLP1) receptor agonist use does not appear to be associated with an increased risk for thyroid cancer, according to a study published online April 10 in The BMJ. Björn Pasternak, M.D., Ph.D., from...

Breast Cancer

OBGYN & Women's Health

Oncology

Mortality Up for Breast Cancer Diagnosed Five to <10 Years After Childbirth

Increased risk for all-cause mortality seen with postpartum young-onset breast cancer in women with germline BRCA pathogenic variants Young-onset breast cancer (YOBC) with germline BRCA pathogenic variants (PVs) is associated with an increased risk for all-cause mortality if diagnosed within 10 years after childbirth, according to a study published online April 19 in JAMA Network Open. Zhenzhen Zhang,...